As a targeted drug, sotoracib (AMG510), what is its pricing and latest sales trends on the market?

Sotoraxib (AMG510) is a new type of anti-cancer drug that belongs to the tyrosine kinase inhibitor (TKI) category. It is an orally available small molecule drug that specifically inhibits the activated state of the mutant KRAS G12C protein in tumor cells, thereby blocking the protein's role in the signal transduction pathway. The KRAS G12C mutation is a common cancer-related mutation found in a variety of cancers, such as non-small cell lung cancer (NSCLC).

The mechanism of action of the drug Sotoraxib enables it to selectively inhibit the growth and spread of malignant tumors caused by KRAS G12C mutations, thereby providing an effective treatment option for patients with such tumors. Sotoracib is a targeted therapy drug that has higher specificity and lower toxic side effects than traditional chemotherapy drugs. At present, sotoraxib has shown good efficacy and safety in clinical trials and is considered an innovative drug that is expected to change the treatment landscape of KRAS G12C mutated malignant tumors.

The original drug of sotorasibu has not yet been launched in China, so it is not included in the scope of medical insurance. Domestic patients cannot yet purchase this drug. The price of the original Hong Kong version of sotorasibu (120mg*240 tablets) is around RMB 80,000, while the price of the original European version (120ng*240 tablets) is more than RMB 40,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs sold in other countries. The ingredients of the two drugs are basically the same. For example, the price of 120mg*56 tablets produced by Laos Lucius Pharmaceutical Factory is more than 1,000 yuan per box, while the price of each box of Daxiong Pharmaceutical is more than 2,000 yuan (the price may fluctuate due to the exchange rate).